Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors

Grant

Total Award Amount

  • 144300.00
  • Direct Costs

  • 111000.00
  • Sponsor Award Id

  • Contributor

  • ealva   Investigator  
  • eejohnst   Investigator  
  • jamieaye   Investigator  
  • kifowler   Investigator  
  • kmetrock   Investigator  
  • gkf   Principal Investigator